ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Next Generation Development of Broadly Neutralizing HIV Antibodies for Prevention

Active
Institution
ADVANCED BIOSCIENCE LABORATORIES, INC., MD
Principal investigator
Timothy Fouts
Funding
$181K
Duration
2025–2028
Open portfolio

Moonbase score

Still being scored

Abstract

HIV broadly neutralizing antibodies (bnAbs) are currently being evaluated in clinical trials for both HIV treatment and prevention indications - including VRC01, a CD4-binding site monoclonal antibody (bnMAb), in the current AMP clinical trial HVTN 704/HPTN 085. Current studies indicate that 2 or more bnAbs targeting different epitopes will probably be needed for successful treatment and prevention regimens. PGDM1400 and PGT121 are two bnAbs that recognize unique epitopes on the HIV envelope protein and could be used in addition to VRC01 for coverage. Clinical trials are currently evaluating these antibodies; however, the current clinical trial material for these antibodies do not have half-life extension mutations that would greatly improve their half-life and mitigate adherence issues commonly seen with current ART and preventative measures.

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESN01epitopesneutralizingbnabsantibodiestreatment preventionhalf-lifehivbroadly neutralizing

Questions for ADVANCED BIOSCIENCE LABORATORIES, INC.

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.